Alkermes raises offer for Avadel after Lundbeck bid

Alkermes has raised its takeover bid for Avadel Pharmaceuticals to $21 per share in cash plus a $1.50 contingent value right tied to FDA approval of Avadel’s sleep disorder drug Lumryz for idiopathic hypersomnia by end-2028, a package that values Avadel at up to $2.37 billion and beats a rival proposal from Denmark’s Lundbeck. The revised offer supersedes Alkermes’ earlier $18.50-per-share cash proposal (plus the same $1.50 CVR, previously valuing the deal at up to $2.1 billion) and compares with Lundbeck’s proposal of up to $23 per share consisting of $21 cash and up to $2 in sales-based milestones. The competition underscores the strategic importance of Lumryz and leaves the deal’s ultimate payoff contingent on regulatory approval timing and future U.S. commercial performance.

Analysis

Alkermes has raised its takeover bid for Avadel to $21 per share in cash plus a $1.50 contingent value right (CVR) payable if the FDA approves Avadel's Lumryz for idiopathic hypersomnia by end-2028, a package that values Avadel at up to $2.37 billion. This supersedes Alkermes' prior $18.50 cash plus $1.50 CVR offer (previously valuing the deal at up to $2.1 billion) and comes in response to a rival Lundbeck proposal of up to $23 per share composed of $21 cash and up to $2 in U.S. sales-linked milestones. The competing structures allocate risk differently: Alkermes' CVR is tied to regulatory approval timing while Lundbeck's contingent payments are tied to future commercial performance, leaving the realized consideration dependent on approval probability and market uptake. Market signals show a mildly positive tone (sentiment score 0.28) with stronger positive sentiment for Avadel (0.8) than for Alkermes (0.2), reflecting more immediate upside for Avadel shareholders but regulatory and execution uncertainty for the acquirer. Key near-term catalysts are Avadel's board response, any topping bids, and FDA regulatory milestones for Lumryz through 2028, which will determine ultimate deal value and merger probability.

Key Decisions for Investors

• Avadel shareholders should model the probability-weighted value of Alkermes' $1.50 FDA-tied CVR versus Lundbeck's up-to-$2 sales milestones and delay tender decisions until the board recommendation or a higher firm bid emerges
• Investors in Alkermes should monitor deal financing, potential dilution and integration plans and limit incremental exposure until regulatory-contingent liabilities and CVR accounting are disclosed
• Event-driven traders should prioritize FDA timelines, any Avadel board statement and competing-bid updates as primary triggers for share-price moves and consider short-dated positions around these announcements
• Consider hedging positions (options or protective collars) if holding Alkermes through the approval window, given the deal's sensitivity to FDA timing and the possibility of a renewed bidding process